AKF 1Alternative Names: AKF-1
Latest Information Update: 26 Nov 2015
At a glance
- Originator Akorn
- Class Antiallergics; Eye disorder therapies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Allergic conjunctivitis
Most Recent Events
- 26 Nov 2015 No recent reports on development identified - Phase-III for Allergic conjunctivitis in USA (Ophthalmic)